USA-based Impax Laboratories (Nasdaq: IPXL) has become the latest company to buy up assets being sold by Israeli generics giant Teva Pharmaceutical Industries (NYSE: TEVA) in a $586 million deal.
Teva is offloading certain assets as a pre-condition of its $40.5 billion purchase of the generics business of Ireland-incorporated Allergan (NYSE: AGN) to avoid the merged entity breaching competition requirements.
The latest sell-off will see Impax gaining a broad portfolio of generic products across solid oral, inhalable, injectable and topical dosage forms, and regain the rights to the pending abbreviated new drug application (ANDA) for the generic equivalent to the central nervous system stimulant Concerta (methylphenidate hydrochloride).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze